Filing Details

Accession Number:
0001209191-17-060104
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-11-09 19:47:44
Reporting Period:
2017-11-07
Accepted Time:
2017-11-09 19:47:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1479290 Revance Therapeutics Inc. RVNC Pharmaceutical Preparations (2834) 770551645
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1529196 J Mark Foley C/O Revance Therapeutics, Inc.
7555 Gateway Blvd.
Newark CA 94560
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-11-07 19,500 $26.95 19,500 No 4 P Indirect See footnote
Common Stock Acquisiton 2017-11-07 500 $27.45 20,000 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 6,000 Direct
Footnotes
  1. The price reported in Table I, Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.425 to $27.425. Mr. Foley undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  2. These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.